Atlas
Market PulseSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › ANTHEM

ANTHEM

Anthem Biosciences Limited
Mid-capPharma ↗

What the six lenses say about ANTHEM — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹752.0
2026-07-10
VWAP · 1Y anchor
₹745
+0.9% from VWAP
P/E · TTM
71.3×
TTM EPS ₹10.5
52-week range
59%
position low→high
RSI(14)
43
momentum

Own sector index

Pharma ↗
Overweight

1M

+6.2%

3M

+15.8%

1Y

+16.2%

Breadth >EMA21

72%

How ANTHEM’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
6.0
avg conviction decile
Leadership
0/2
active lenses · Tech & Flow
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Mid-cap cohortDRaw
TechnicalD783›

The actual numbers

Price vs VWAP (1y)+0.9%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+2.8%
Price vs 50-EMA-1.0%
RSI(14)43
RS vs Nifty 500 · 3M-2.3%
RS vs sector · 3M-14.7%
52-week range59%
Volume vs 30d avg0.58×
Volume vs 60d avg0.70×
ATR(14) · volatility20.8
Bollinger width · vol contraction0.060
FundamentalD1087›

The actual numbers

Return on equity (ROE)22.3%
Return on capital (ROCE)30.4%
Operating margin39.1%
Net margin27.9%
Revenue growth · YoY+15.1%
EPS growth · YoY+30.6%
Debt / equity0.02×

Full 8-quarter history in the financials table below.

ValuationD28›

The actual numbers

P/E (TTM)71.3×
TTM EPS₹10.5
52-week range59%
CatalystD333›

The actual numbers

Earnings & momentum38
Capital actions13
Governance55

Every filing in the corporate-announcements panel below.

FlowD550›

The actual numbers

Promoter holding74.7%
Delivery · 30d avg55.4%
Up/down-day asymmetry-1.2pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Mid-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D7 + D5 ) ÷ 2 = 6.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
79
Conviction score 79/100 · avg-decile strength 6.0/10
Conviction score79/100›
TechnicalD7›
FundamentalD10›
ValuationD2›
CatalystD3›
FlowD5›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-07-10.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+0.1pp
-1.8pp
-5.1pp
+1.4pp
+26.1pp
—
Nifty 500
Broad-market baseline
-0.3pp
-1.8pp
-5.6pp
-2.3pp
+21.1pp
—
Sector
Own-sector index
—
—
-8.0pp
-14.7pp
+6.7pp
—

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

ANTHEM daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
752.00+3.55

Relative strength

RS vs baseline · rebased to 100

ANTHEM ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
104.29-0.29

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)339525498483540550423611
↳ change QoQ—+54.9%-5.1%-3.0%+11.8%+1.9%-23.1%+44.4%
EBITDA (₹cr)121195160195191218157267
EBITDA margin35.7%37.1%32.1%40.4%35.4%39.6%37.1%43.7%
PAT (₹cr)821621248313617393190
↳ change QoQ—+97.6%-23.5%-33.1%+63.9%+27.2%-46.2%+104.3%
Net margin24.2%30.9%24.9%17.2%25.2%31.4%22.0%31.1%
EPS (₹)1.472.902.221.482.423.091.653.38
D/E————————
YoY growth · Mar '26Revenue +26.5% YoYPAT +128.9% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 17 Jun '26
    HIGHearnings
    Clarification - Financial Results
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 16 Jun '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 20 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 19 May '26
    LOWgovernance
    Change in Management
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 19 May '26
    MEDIUMcapital
    Dividend
    ›

    A dividend declaration — a cash return to shareholders.

    View original filing on NSE ↗
  • 19 May '26
    LOWgovernance
    ESOP/ESOS/ESPS
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 19 May '26
    MEDIUMcapital
    Press Release (Revised)
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 19 May '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 19 May '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 19 May '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 19 May '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 12 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds ANTHEM

Mutual funds holding ANTHEM (10)

FundWeightAUM ₹crGrade
HDFC Flexi Cap Gr0.57%1,01,822
Quant Small Cap Gr0.88%31,774
Axis ELSS Tax Saver Fd Gr0.61%31,023
Aditya BSL Flexi Cap Gr0.72%26,032
SBI Midcap Reg Gr1.38%24,127
Axis Large & Mid Cap Reg Gr0.51%15,879
Axis Flexi Cap Reg Gr0.72%12,625
UTI Mid Cap Reg Gr0.80%12,122
PGIM India Midcap Fund Reg Gr0.65%10,822
Kotak Large Cap Reg Gr0.54%10,772

ETFs holding ANTHEM (0)

No tracked ETF holds ANTHEM ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma